Manhattan Scientifics, Inc. (MHTX)

[ssc]

Interesting. While safety and efficacy are important, the much more significant issue is proving that it works. 7 years testing with mice and still not ready to present a case to the FDA to request approval to just begin a human trial. And the human machine is just now in its design stage.

In light of those facts, and considering how many more years to go before human trial would produce approvable results, I question how you arrived at the conclusion that "they shouldn't run out of cash".

Latest report from ibx states $7 million in cash left, burning $1 million/quarter PLUS costs of outsourcing which will include the large tasks of designing and building a human machine and the manufacturing of nano particles. Then add in the costs of trials to prove the safety and efficacy you mentioned, and the cost of human trials.

Anyone wondering why the ibx price has fallen need only look at the cash requirements to get from here to the end of human trials and it should be clear that the $7 million won't last very long and that further substantial dilution is inevitable.